Clinical Trial Update: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and immunogenicity of two doses of an H5N1 influenza vaccine in elderly adults; results were completed and posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Subtype H5n1 Infection

Drugs mentioned

• H5N1 influenza vaccine (influenza vaccine H5N1)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic H5N1 Influenza | Phase 2 | Status: COMPLETED | Results posted: 2015-08-10